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Abstract
Introduction: We investigated the frequency of detection and the prognostic and predictive significance of circulating
tumor cells (CTCs) in patients with recurrent/metastatic (R/M) head and neck carcinoma (HNC) before starting systemic
therapy.
Patients and methods: Using the CellSearch technology, CTCs were assessed prospectively in peripheral blood of 53 R/M-
HNC patients. We performed spiking experiments to test the diagnostic performance of the CellSearch platform in
identifying squamous carcinoma cells.
Results: CTCs were identified in 14 (26%) and 22 (41%) patients at baseline and at any time point, respectively. In univariate
analysis $2 CTCs had a poorer prognostic role than 0–1 CTC. In multivariate analysis, the presence of one CTC or more was
associated with a poor prognosis both in terms of progression-free survival (PFS) [Hazard Ratio (HR): 3.068, 95% confidence
interval (CI): 1.53–6.13, p 0.002] and overall survival (OS) [HR: 3.0, 95% CI: 1.48–6.0, p 0.002]. A disease control after systemic
therapy was obtained in 8% of CTC-positive patients as opposed to 45% in CTC-negative ones (p 0.03). The epidermal
growth factor receptor (EGFR) expression was identified in 45% of CTC-positive patients.
Discussion: In conclusion, CTCs are detected in one out of three patients with RM-HNC. CTC detection is a strong prognostic
parameter and may be predictive of treatment efficacy. The frequency of EGFR expression in CTCs seems to be lower than
that expected in the primary tumor.
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Introduction
Squamous cell carcinoma of the head and neck (HNC) is the
sixth most common cancer worldwide. Concomitant chemo-
radiotherapy (CRT) has improved survival and organ preservation
in patients with locally advanced disease [1], however treatment
failure is observed in more than 50% of cases with stage III–IV
tumors. The median survival of patients with persistent, recurrent
or metastatic HNC is less than 12 months [2]. Salvage surgery or
re-irradiation have a limited benefit at the price of a high
incidence of treatment-related morbidity [3]. Systemic chemo-
therapy including platin-salts agents in combination with infu-
sional fluorouracil and/or a taxane plus/minus the anti-EGFR
monoclonal antibody cetuximab is frequently adopted [2–4].
Systemic therapy, however, is effective in approximately one third
of patients. The characterization of the patient subset destined to
have a relatively long survival and obtain benefit from therapy is
crucial to tailor individually the best treatment approach and
avoid unnecessary side effects. In a retrospective analysis of 390
metastatic patients treated with chemotherapy, Argiris et al.
identified a set of five clinic-pathological variables (ECOG
performance status, weight loss, location of the primary tumor,
prior radiotherapy and tumor cell differentiation) with prognostic
significance. This model was also predictive of response to
chemotherapy [5], however it is not validated.
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Circulating tumor cells (CTCs) can provide meaningful,
‘‘realtime’’ information on the biology and clinical behavior of
many tumors [6–9]. CTCs are very rare in the blood and, to date,
the only standardized and highly reproducible assay, is the
CellSearch system (Veridex, Raritan, NJ, USA) a method based
on the Epithelial Cell Adhesion Molecule (EpCAM)-specific
immunomagnetic separation [10]. The presence of CTCs has
already been described in HNC patients, however most studies
employed unstandardized systems including immunomagnetic
negative separation, flow-cytometry, immunocytochemistry and
RT-PCR [11–15]. Previous reports of EpCAM expression in
carcinomas of the head and neck district showed that EpCAM is
overexpressed in approximately 22%–75% of oropharyngeal and
larynx carcinomas, in 86% of squamous cell carcinomas of the
cervical esophagus and in 83%–100% of salivary glands carcino-
mas with different immunostaining intensities [16–17]. Further-
Table 1. Patients characteristics at baseline.
Evaluable patients (n=53)
Characteristic n (%)
Age (years) Median 59
Range 20–79
,70 years 42 (79)
$70 years 11 (21)
Sex Male 42 (79)
Female 11 (21)
Baseline ECOG performance status 0 12 (23)
1 27 (51)
2 13 (24)
3 1 (2)
N. of Argiris factors 0–2 14 (26)
$3 39 (74)
Weight loss ,5% 29 (55)
$5% 24 (45)
Alcohol abuse Yes 26 (49)
No 27 (51)
Smoking history Yes 46 (87)
No 7 (13)
Anatomic distribution of primary tumor Nasopharynx 4 (8)
Nasal sinus 4 (8)
Oral cavity 17 (32)
Oropharynx 7 (13)
Hypopharynx 4 (8)
Larynx 15 (28)
Cervical esophagus 2 (3)
Tumor grade 1–2 44 (83)
3 9 (17)
Disease extent Locally advanced 26 (49)
Metastatic 27 (51)
No of disease sites 1 30 (56)
2 20 (38)
3 2 (4)
4 1 (2)
Prior treatments for primary tumor Surgery 32 (60)
Radiotherapy 34 (64)
Chemotherapy 15 (28)
N. of prior chemotherapy lines for metastatic disease 0 40 (75)
1 7 (13)
2 1 (2)
3 5 (10)
doi:10.1371/journal.pone.0103918.t001
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more, CTCs have been identified by means of the CellSearch in
28%–77% of squamous cell carcinomas of the lung [6,18].
Our group conducted a multi-center prospective study to verify
the presence and clinical utility of CTCs as measured by the
CellSearch platform in patients with locally advanced and R/M-
HNC. Previously, we reported a correlation between variation of
CTCs numbers and response to chemo-radiotherapy in patients
with non-metastatic HNC [19]. The current study was undertaken
to demonstrate the proportion of R/M patients with detectable
CTCs. Secondary aims were to provide information on 1) the
prognostic significance of the presence of CTCs in this setting, 2)
the role of CTCs detection in predicting treatment response and 3)
the frequency of expression of EGFR in CTCs.
Patients and Methods
Ethics statement
This diagnostic observational study was conducted at three
Oncology Institutions in Italy. The Institutional Ethics Review
Board at the Spedali Civili of Brescia (Coordinating Centre)
approved the study as part of a wider project of CTC
determination in patients with solid neoplasms. However, because
of the non interventional nature of the trial and because the
patient’s clinical management was not influenced by the study
results, the other participating centers (Department of Radiother-
apy Oncology, University Hospital Careggi of Florence and
Department of Radiotherapy Oncology, AUSL-4 of Prato,
respectively) approved the study without a formal review by the
Ethics Committee Boards. All patients provided a written
informed consent for diagnostic and research procedures. The
present work was performed in accordance to the ethical principles
for medical research involving human subjects of the Helsinki
Declaration.
Study design, patients and treatments
Patient inclusion criteria were a histology-proven diagnosis of
squamous carcinoma of the HN region, recurrent or metastatic
disease with measurable lesions according to RECIST criteria.
Exclusion criteria included poor performance status (ECOG.2)
and other concomitant neoplasms. Patients were addressed to
either chemotherapy or palliative care when indicated. Chemo-
therapy was administered as first or subsequent line for recurrent/
metastatic disease. Blood for CTC detection was planned to be
collected at baseline, after 3 chemotherapy cycles and at treatment
completion or progression (PD). Disease status was monitored
clinically and by imaging technique at the same time points.
Disease control was defined as complete response (CR), partial
response (PR) or stable disease (SD). Clinical variables included
age, sex, ECOG performance status, weight loss, alcohol, smoking
history, histology, grade of differentiation, head and neck primary
sub-site, site of relapse, number of metastatic sites, previous
treatment and response to chemotherapy. The Argiris prognostic
score was also calculated. (Clinical data are accessible in Data S1).
Blood collection, isolation and enumeration of CTCs
Blood from HN cancer patients was drawn into 10 mL
evacuated tubes which contained a cell preservative (CellSave
Preservative Tubes, Veridex LLC, Raritan, NJ, USA). Blood from
nine normal (ie without previous history or evidence of any
neoplasm) individuals as negative controls was also drawn to
confirm that CTCs do not circulate in the blood of individuals
without cancer. All of them received a clinical examination to
confirm absence of either neoplastic or preneoplastic lesions or
inflammatory diseases of the HN district at the time of analysis. All
Figure 1. Recovery efficiency of known numbers of spiked A-
431 cells from 7.5 mL of blood. The number of spiked cells is
plotted against cells recovered by the CellSearch. The Pearson
correlation value (R2) indicates strong correlation between spiked and
recovered cells.
doi:10.1371/journal.pone.0103918.g001
Table 2. CTCs prevalence in recurrent/metastatic head and neck cancer patients.
Characteristic n (%)
Evaluable patients 53 (100)
CTCs+ pts at baseline 14 (26)
CTCs numbers at baseline Median CTCs 1
Mean CTCs 6 SD 5610
Range 1–43
CTCs+ pts at anytime 22 (41)
N. of CTCs determinations 1 16 (31)
2 21 (39)
3 5 (9)
4 11 (21)
doi:10.1371/journal.pone.0103918.t002
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CTC analyses were centralized at the Spedali Civili of Brescia and
blood samples from peripheral participating centers were sent out
by courier. Blood samples were maintained at room temperature
and processed for CTC enumeration within 96 hours from
collection following the manufacturer’s instructions.
CellSearch assay efficiency of squamous CTCs detection
As the CellSearch system is approved by the US Food and Drug
Administration (FDA) for the detection of CTCs from various
adenocarcinomas [7–9], we sought to verify whether the system
was also able to detect cells from squamous carcinomas. In order
to estimate the accuracy of the CellSearch System in detecting
CTCs in HN neoplasms, we conducted spiking experiments as
previously reported [20]. Briefly, three 7.5 mL aliquots of blood
from 3 normal blood donors were collected into CellSave
Preservative Tubes. The three aliquots from each donor were
spiked with different numbers of A-431 cells (ATCC, Rockville,
MD, USA), a human squamous cell carcinoma cell line positive for
both EpCAM and cytokeratins (Figure S1), to produce separate
tubes with 80, 20 and 5 cells per 7.5 mL of blood. Briefly, the
human A-431 cell line was cultured in flasks and subsequently
harvested by trypsin treatment. Exact concentration of cells per
volume (cells/ml) was determined by flow cytometry-based single
platform approach using tubes containing pre-determined num-
bers of microbeads (TruCount, BD Biosciences, San Jose, CA,
USA). Analysis was performed using a flow cytometer (FACS-
Canto II, BD Biosciences, San Jose, CA, USA) by a specific gating
strategy in single platform assay. After having determined the
exact number of cells present in stock sample, consequent dilution
was performed and final concentration of A-431 cells was
confirmed applying the same counting strategy. Therefore, 80,
20 and 5 A-431 cells were spiked in triplicate in the Cell Save
sample tubes. All tubes were mixed by repeated inversion and
Table 3. Univariate associations between CTCs at baseline and clinico-pathologic characteristics.
Characteristic
N. pts with $1CTC at
baseline/total (%)
Fisher’s exact test
p
Age (years) ,70 years 13/42 (31) .251
$70 years 1/11 (9)
Sex Male 12/42 (28) .706
Female 2/11 (18)
Baseline ECOG PS 0 5/23 (22) .547
$1 9/30 (30)
Weight loss ,5% 7/29 (24) .760
$5% 7/24 (29)
Alcohol abuse Yes 8/26 (31) .544
No 6/27 (22)
Smoking history Yes 13/46 (28) .660
No 1/7 (14)
Main HN anatomical grouping Upper HN (nasoph+nasal sinus) 2/8 (25) .916
Mid HN (oroph+oral cavity) 7/24 (29)
Lower HN (larynx+hypoph+esoph) 5/21 (24)
Tumor grade 1–2 14/44 (32) .092
3 0/9 (0)
Relapse/recurrent disease Local 6/26 (23) .757
Distant 8/27 (30)
No of sites of metastasis 1 5/30 (16) .115
.1 9/23 (39)
M+ de novo vs relapsed De novo 3/15 (20) .732
Relapsed 11/38 (29)
Prior surgery for primary tumor Yes 8/31 (26) 1.0
No 6/22 (27)
Prior RT for primary tumor Yes 9/36 (25) .748
No 5/17 (29)
Prior CT for primary tumor (concomitant/neoadjuvant) Yes 4/25 (16) .225
No 10/28 (36)
N. of prior CT lines for metastatic disease 0 10/40 (25) .725
$1 4/13 (31)
N. of Argiris factors 0–2 3/14 (21) .735
$3 11/39 (28)
doi:10.1371/journal.pone.0103918.t003
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allowed to sit overnight at room temperature. On the following
day, all the nine tubes were processed and analysed by a single
operator according to the manufacturer’s instructions. The
Pearson correlation analysis was used to establish association
between CellSearch-recovered versus spiked CTC counts.
EGFR analysis on CTCs from R/M-HNC
To measure the percentage of EGFR-positive CTCs from R/
M-HNC we used the commercially available CellSearch Tumor
Phenotyping Reagent EGFr kit (Veridex LLC, Raritan, NJ, USA)
on the fourth channel of fluorescence of the CellSearch system
following the manufacturer’s instructions. The analytical sensitivity
Figure 2. Kaplan-Meier curves of (A) progression-free survival and (B) overall survival in patients with 0, 1 and $2 CTCs.
doi:10.1371/journal.pone.0103918.g002
Figure 3. Kaplan-Meier estimates of overall survival according to a combined risk factors model with Argiris factors and CTCs.
Continuous line indicates absence of both risk factors; small dotted line indicates the presence of only one of the two risk factors; large dotted line
indicates the presence of both risk factors.
doi:10.1371/journal.pone.0103918.g003
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of this kit has not been reported by the manufacturer and we
analysed cell lines with different (or absent) levels of expression of
EGFR to test the diagnostic performance of the procedure. The
CellSearch was able to correctly detect all the spiked cells from the
three EGFR-positive cell lines as EGFR-positive and correctly
identified the EGFR-negative cell line as EGFR-negative. (data
not shown).
Statistical analysis
The primary objective of the study was to assess the frequency
of CTCs in the peripheral blood of patients with RM-HNC
measured by the CellSearch system. The sample size was
calculated in order to reject the null hypothesis that the proportion
of patients with detectable CTC was less than 5% and to provide a
statistical power of 80% to demonstrate that at least 35% of
patients had at least 1 CTC/7.5 mL. With a two-sided alpha of
0.05, 50 consecutive patients meeting the inclusion criteria were
planned to be enrolled. Secondary objectives were to correlate the
presence of CTCs with outcome endpoints and response to
chemotherapy.
The relationship between categorical covariates was assessed
with a Fisher’s exact test. PFS and OS were defined as the time
elapsed from baseline CTC analysis to the first evidence of disease
progression and death or last follow-up, respectively. Survival
curves were calculated with the Kaplan Meier method and
compared with the log-rank (Mantel-Cox) test. Cox proportional
hazard model was employed to assess the HR of progression and
death both in uni- and multivariate analyses. All tests were two-
sided and the p,.05 was considered statistically significant.
Statistical analyses were conducted with the SPSS software (SPSS
version 17.0, Chicago, IL, USA). The REporting of tumor
MARKer Studies (REMARKS) guidelines were followed in
reporting results of this study [21].
Results
Patient demographics
From January 2009 to February 2011, 57 consecutive patients
were enrolled in the study. Four patients were not evaluable, two
because of technical defaults of the CellSearch system and two
because of lack of clinical information. The characteristics of the
final 53 evaluable patients are outlined in Table 1. The vast
majority of patients had a squamous cell carcinoma. Four patients
had an undifferentiated carcinoma of the nasopharynx. Fifteen
(28%) patients were metastatic at diagnosis and 38 had recurrent
disease. Forty patients (75%) were chemotherapy-naı¨ve. Chemo-
therapy was administered to 45/53 (85%) patients while 8 patients
with severe comorbidities received best supportive care. Chemo-
therapy consisted of cisplatin monotherapy in 1 patient (2%),
cisplatin plus fluorouracil in 16 (36%) patients, cisplatin, fluoro-
uracil and paclitaxel in 21 (46%) patients, cisplatin and cetuximab
in 1 patient (2%), methotrexate in 4 (9%) patients and vinorelbine
in 2 (4%) patients. In the group of nine individuals selected as
negative controls, median age was 51 years, 6 were males and 3
were females.
CellSearch assay efficiency of squamous CTCs detection
The approximate number of A-431 cells spiked into the blood of
the three healthy donors was plotted against the number of the
CellSearch-recovered cells in the samples and regression analysis
using the number of observed CTCs versus the number of
expected CTCs resulted in a best fit line with a slope of 1.03
(95%CI: 0.77–1.3), an intercept of 21.57 (95%CI:213.9–10.8),
and a correlation coefficient (R2) of 0,9996 (Figure 1). The assay
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efficiency of recovery was .90%, indicating that the platform was
able to detect squamous cells.
CTCs assessment
Thirty-seven patients had CTC assessed at least at two time
points while sixteen patients had only one sample evaluated.
Twenty-two (41%) patients had detectable CTCs at least at one
time point during clinical observation. In patients with detectable
CTCs, median and mean CTCs values were 1 and 5 (610 SD),
respectively. We therefore used 1 CTC/7.5 mL as cutoff for
subsequent analyses. At baseline, 14 (26%) patients had at least 1
CTC detected. Nine of them (64%) had 1 CTC, two (14%) had 2–
10 CTCs and three (20%) more than 10 CTCs (Table 2). None of
the nine normal volunteers had detectable CTCs. At univariate
analysis the presence of CTCs at baseline was not related to any of
the clinical variables considered. (Table 3).
Prognostic significance of CTCs in HNC patients
At the date of last follow-up (March 2012) all patients had
progressed and died. In the overall population median PFS and
OS from CTC analysis were 4 and 7 months, respectively. Median
PFS in patients with 0, 1 and $2 CTCs at baseline were 5 months
(95% CI 3.9–6.0), 5 months (95% CI 0.1–10.8) and 1 month (95%
CI 0.8–1.6), respectively, (log-rank test p,.0005). Median OS in
patients with 0, 1 and $2 CTCs at baseline were 9 months (95%
CI 6.9–11.0), 7 months (95% CI 4.2–9.7) and 2 months (95% CI
0.1–4.1) respectively, (log-rank test p,.0005) (Figure 2A and 2B).
Figure 4. Association between the presence of CTCs before starting a new line of chemotherapy and response to treatment. Higher
response rate is observed in CTC-negative patients at baseline (A). Dynamic variation of CTCs numbers before and after treatment in patients (n = 10)
with at least two determinations and at least one CTC at any time point. CTCs changes did not correlate with tumor response (B).
doi:10.1371/journal.pone.0103918.g004
Figure 5. Example of CTCs analysis in a patient with mediastinal and axillary nodal metastases from an oropharyngeal squamous
cell carcinoma. (A) the CellSearch output of baseline CTC analysis showing two CTCs with heterogeneous EGFR expression. (B) Timeline of CTC
analysis and treatments. (C) Correlative imaging analysis by CT/PET at baseline and after chemotherapy. In this patient 3 CTCs were detected at
baseline. After 4 cycles of a chemotherapy, CTC number rised to 9 suggesting progressive disease then confirmed by CT/PET imaging.
doi:10.1371/journal.pone.0103918.g005
Circulating Tumor Cells in Metastatic Head and Neck Carcinoma
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These results indicate that $2 CTCs rather than 1 CTC might be
a better cutoff indicator for both PFS and OS.
Combining Argiris factors with CTC results, overall survival
was better in patients with low Argiris risk and no CTC (median
11 months, 95% CI 6.6–15.3) than in patients with high Argiris
risk and at least 1 CTC (median 3 months, 95% CI 1.0–4.9) (log-
rank test p .001) (HR .22, 95% CI .09–.54). Patients with one of
the 2 risk factors had an intermediate survival (median 7 months,
95% CI 5.1–8.8) (HR .52, 95% CI .26–1.0) (Figure 3).
At univariate analysis, variables with statistically significant
impact on PFS and OS were the site of relapse (local vs distant) (p
.015 and p .011, respectively), the Argiris prognostic factors ($3 vs
0–2) (calculated only for OS, p .017) and CTCs at baseline (Table
S1). At multivariate regression analysis, the covariates that
maintained an independent prognostic significance both for PFS
and for OS were CTCs at baseline (HR 3.0, 95% CI 1.53–6.13, p
.002 and HR 3.0, 95% CI 1.48–6.0, p .002) and the site of relapse
(HR 2.68, 95% CI 1.44–4.97, p .002 and HR 2.34, 95% CI 1.14–
4.8, p .019), respectively (Table 4).
CTCs at baseline as predictors of response to
chemotherapy and variation of CTCs number after
chemotherapy
Response to chemotherapy was evaluated in 45 treated patients
after 3 cycles and at treatment completion or progression. Sixteen
(35%) patients obtained disease control (9 PR and 7 SD) and the
remaining 29 (65%) had PD. The clinical control of the disease
was mainly confined in patients with 0 CTC (15/33, 45%) while
only one (8%) PR was observed in the 12 patients with detectable
CTCs at baseline (p .03) (Figure 4A).
Ten out of the 14 CTC-positive patients at baseline were tested
before and after chemotherapy. Of them, five had a increase, one
remained stable and four had a decrease of CTCs after treatment.
By contrast, seven patients without CTCs at baseline had
detectable CTCs at the end of treatment (Figure 4B). As an
example, Figure 5 illustrates the outcome in terms of CTCs and
imaging of a patient progressing after a line of chemotherapy.
Changes in CTCs levels were not found to be correlated with
tumor response.
EGFR characterization of CTCs in HNSCC patients
The EGFR expression was assessed in 41 samples. Of the 22
patients with at least one CTC during clinical observation, 10
(45%) had CTCs with detectable levels of EGFR as measured with
the CellSearch system and 12 (55%) had EGFR-negative CTCs.
Of note, consistent heterogeneity in EGFR expression was
observed intra- and intersample (Figure 5). On average, when
more than one CTC was counted in 7.5 mL of blood, EGFR was
expressed in 25% of the detected CTCs within the same sample.
Furthermore, in 8 patients with EGFR-positive CTCs evaluated at
two or more time points, EGFR was detected in 37% of the
samples indicating that EGFR expression is modulated over time
within the same patient.
Discussion
This study demonstrated that 26% of R/M-HNC patients at
baseline conditions and 41% at any time point had $1 CTC. The
spiking experiments performed with the EpCAM-positive cell line
A-431 confirmed that the CellSearch technology can detect
squamous CTCs in blood. These results are in line with recent
experiences in which 16%–40% of stage III–IV HNC patients had
0–2 CTCs by the CellSearch [22,23].
The low median numbers of CTCs detected in HNC patients
by the CellSearch test could reflect a true low frequency of CTCs
in HNC or may be the result of an intrinsic low expression of the
capture antigen, EpCAM molecule, on cancer cells surface.
Alternatively it suggests the existence of epithelial-to-mesenchymal
transition (EMT) phenomena with a higher number of circulating
cancer cells lacking epithelial markers such as EpCAM or
cytokeratins [24,25].
There is an urgent need of prognostic and predictive factors in
recurrent/metastatic-HNC patients and our results showed that
CTCs could serve as new independent prognostic parameter for
both PFS and OS. In univariate analysis .2 CTCs had a poorer
prognostic role than 0–1 CTC in patients before starting a new
chemotherapy. However, this effect was observed also at any time
point during clinical observation (data not shown).
The largest analysis of prognostic factors in recurrent and
metastatic HNC, published by Argiris et al, identified a set of
clinico-pathological factors that correlated with the patient
outcome [5]. Noteworthy, in our study, after adjustment for the
presence of CTCs, the Argiris criteria were no longer prognostic.
By combining Argiris high risk criteria with the presence of CTCs
we found a good separation in terms of survival among patients
with both risk factors, one risk or none of the two. These data
confirm the emerging evidence that the presence of cancer cells in
the blood is per se associated with more aggressive features of the
neoplasm, independently of the patient characteristics and the
tumor stage. Another interesting aspect of our study was that there
was no difference in terms of CTCs between patients with local
recurrence or distant metastases. This result suggests that HNC,
traditionally considered a disease with local tropism, is indeed
characterized by circulation and re-circulation of cancer cells via
the bloodstream regardless of the metastatic site, local or distant
[26].
In our series the presence of CTCs was also predictive of
chemotherapy activity. The clinical control of the disease, in fact,
was mainly confined in patients with 0 CTC as opposed to their
counterpart. Again, it could be hypothesized that those cancer
cells that enter into the blood have acquired more aggressive
features than resident cancer cells, including enhanced survival
and chemoresistance [27]. Thus, the presence of CTCs before
starting a new chemotherapy or their appearance during
treatment could identify poor-responder patients. This interesting
observation deserves confirmation.
CTCs offer the unique opportunity to monitor the changes in
tumor biology over time. EGFR is overexpressed in over 90% of
HNC [28] although with a wide range of expression [29]. In this
work, the CellSearch was able to identify EGFR signals in 45% of
patients with CTCs at any time point. These data suggest a huge
discordance of EGFR expression between the primary tumor and
CTCs and this could indicate a modulation of EGFR expression
over time. Similar findings were already described in metastatic
breast cancer patients in whom a discordance rate of 42% in terms
of Her2-positivity between primary breast cancer and CTCs was
observed [30]. Again, given that EMT processes induce down-
regulation of epithelial markers and that EMT facilitates
intravasation of cancer cells within the bloodstream [31], the
presence of EGFR-negative CTCs could identify cancer cells with
more proclivity to metastasize.
EGFR determination by immunohistochemistry (IHC), either in
the primary or in metastatic lesions, is not required for Cetuximab
prescription according to both FDA and EMEA guidelines. In the
Extreme trial, response rate in the Cetuximab arm was 36%.
However, neither EGFR expression by IHC nor EGFR gene copy
number by FISH in the primary tumor were found to be
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predictive of response in two retrospective analyses [32,33]. Based
on our results, evaluation of EGFR expression on CTCs could be
prospectively analyzed in Cetuximab-treated patients to establish
possible predictive significance.
In conclusion, this paper demonstrates for the first time that
CTCs can be detected in one third of patients with RM-HNC and
their presence strongly correlates with unfavorable prognosis
independently of tumor and patient’s characteristics. Our data also
suggest a role of CTCs in predicting the treatment activity,
although these results must be interpreted with caution. The
clinical and therapeutic implications of CTCs in HNC and their
molecular heterogeneity deserve to be further studied.
Supporting Information
Figure S1 Phenotype analysis of the A-431 squamous
cell line in terms of EpCAM, cyokeratins and EGFR
expression.
(TIF)
Table S1 Univariate analysis of progression-free and
overall survival.
(DOCX)
Data S1 (SAV)
Acknowledgments
The authors wish to thank Dr. S. Marzano, Dr. M. Spediacci and Dr. C.
Polli of the Department of Radiation Oncology, ASL4, Prato, Italy for
their contribution in this study. The contribution of the nursing staff and
participating patients and their families is also acknowledged.
Author Contributions
Conceived and designed the experiments: SG CA MB. Performed the
experiments: SG CA RV A. Bianchetti. Analyzed the data: SG FC CC CA.
Contributed reagents/materials/analysis tools: RV FC MB ABV M.
Mangoni LF GB VDF PN SMM M. Marini. Contributed to the writing of
the manuscript: SG CA A. Berruti. Statistical analysis: SG CC A. Berruti.
Administrative and financial support: M. Marini GB SMM.
References
1. Pignon JP, Le Maitre A, Bourhis J (2007) Meta-analyses of chemotherapy in
head and neck (MACH-NC): an update. Int J Rad Oncol Biol Phys 69: s112–
s114.
2. Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic
head and neck cancer. Ann Oncol 21: vii252–vii261.
3. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ (2004) Treatment of recurrent
and advanced stage squamous cell carcinoma of the head and neck. Sem Radiat
Oncol 14: 190–195.
4. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, et al. (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med 359: 1116–1127.
5. Argiris A, Li Y, Forastiere A (2004) Prognostic factors and long-term
survivorship in patients with recurrent or metastatic carcinoma of the head
and neck. Cancer 101: 2222–2229.
6. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, et al. (2011) Evaluation
and prognostic significance of circulating tumor cells in patients with non-small-
cell lung cancer. J Clin Oncol 29: 1556–1563.
7. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004)
Circulating tumor cells, disease progression, and survival in metastatic breast
cancer. N Engl J Med 351: 781–791.
8. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, et al. (2008).
Relationship of circulating tumor cells to tumor response, progression-free
survival and overall survival in patients with metastatic colorectal cancer. J Clin
Oncol 26: 3213–3221.
9. De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, et al. (2008)
Circulating tumor cells predict survival benefit from treatment in metastatic
castration-resistant prostate cancer. Clin Cancer Res 14: 6302–6309.
10. Mostert B, Sleijfer S, Foekens JA, Gratama JW (2009) Circulating tumor cells
(CTCs): detection methods and their clinical relevance in breast cancer. Cancer
Treat Rev 35: 463–474.
11. Partridge M, Brakenhoff R, Phillips E, Kulsan A, Francis R, et al. (2003)
Detection of rare disseminated tumor cells identifies head and neck cancer
patients at risk of treatment failure. Clin Cancer Res 9: 5287–5294.
12. Wirtschafter A, Benninger MS, Moss TJ, Umiel T, Blazoff K, et al. (2002)
Micrometastatic tumor detection in patients with head and neck cancer. Arch
Otolaryngol Head Neck Surg 128: 40–43.
13. Tong X, Yang L, Campbell Lang J, Zborowski M, Chalmers JJ (2007)
Application of immunomagnetic cell enrichment in combination with RT-PCR
for the detection of rare circulating head and neck tumor cells in human
peripheral blood. Cytometry Part B (Clinical Cytometry) 72B: 310–323.
14. Jatana KR, Balasubramanian P, Lang JC, Yang L, Jatana CA, et al. (2010)
Significance of circulating tumor cells in patients with squamous cell carcinoma
of the head and neck. Arch Otol Head Neck Surg 136: 1274–1279.
15. Hristozova T, Konschak R, Stromberger C, Fusi A, Liu Z, et al. (2011) The
presence of circulating tumor cells (CTCs) correlates with lymph node metastasis
in unresectable squamous cell carcinoma of the head and neck region (SCCHN).
Ann Oncol 22: 1878–1885.
16. Went PTH, Lugli A, Maier S, Bundi M, Mirlacher M, et al. (2004) Frequent
EpCAM protein expression in human carcinomas. Human Pathology 35: 122–
128.
17. Laimer K, Fong D, Gastl G, Obrist P, Kloss F, et al. (2008) EpCAM expression
in squamous cell carcinoma of the oral cavity: frequency and relationship to
clinicopathologic features. Oral Oncol 44: 72–77.
18. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, et al. (2009)
Circulating tumor cells as a diagnostic marker in primary lung cancer. Clin
Cancer Res 15: 6980–6986.
19. Buglione M, Grisanti S, Almici C, Mangoni M, Polli C, et al. (2012) Circulating
tumor cells in locally advanced head and neck cancer: preliminary report about
their possible role in predicting response to non-surgical treatment and survival.
Eur J Cancer 48: 3019–3026.
20. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, et al. (2004) Tumor
cells circulate in the peripheral blood of all major carcinomas but not in healthy
subjects or patients with nonmalignant disease. Clin Cancer Res 10: 6897–6904.
21. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion, et al. (2005)
Reporting recommendations for tumor markers prognostic studies (REMARK).
J Natl Cancer Inst 97: 1180–1184.
22. Nichols AC, Lowes LE, Szeto CCT, Basmaji J, Dhaliwal S, et al. (2012)
Detection of circulating tumor cells in advanced head and neck cancer using the
cellsearch system. Head Neck 34: 1440–1444.
23. Bozec A, Ilie M, Dassonville O, Elodie L, Poissonnet G, et al. (2013) Significance
of circulating tumor cell detection using the CellSearch system in patients with
locally advanced head and neck squamous cell carcinoma. Eur Arch
Otorhinolaryngol 270: 2745–2749.
24. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, et al. (2009) Stem cell and
epithelial-mesenchymal transition markers are frequently overexpressed in
circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res
11: R46. DOI: 10.1186/bcr2333.
25. Bleijerveld OB, Brakenhoff RH, Schaaij-Visser TB, Damen JM, Altelaar AF, et
al. (2011) Protein signatures associated with tumor cell dissemination in head
and neck cancer. J Proteomics 74: 558–566.
26. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, et al. (2009)
Tumor self-seeding by circulating tumor cells. Cell 139: 1315–1326.
27. Gazzaniga P, Gradilone A, Naso G, Cortesi E, Gianni W, et al. (2008)
Chemoresistance profile of circulating tumor cells: toward a clinical benefit?
Int J Cancer 123: 1730–1732.
28. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, et al. (1998) Levels of
TGF-a and EGFR protein in head and neck squamous cell carcinoma and
patient survival. J Natl Cancer Inst 90: 824–832.
29. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, et al. (2002) Impact of
epidermal growth factor receptor expression on survival and pattern of relapse in
patients with advanced head and neck carcinoma. Cancer Res 62: 7350–7356.
30. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, et al. (2009) Correlation of
HER2 status between primary tumors and corresponding circulating tumor cells
in advanced breast cancer patients. Breast Cancer Res Treat 118: 523–530.
31. Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal
transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res
66: 8319–8326.
32. Licitra L, Storkel S, Ferr KM, Van Cutsem E, Pirker R, et al. (2013) Predictive
value of epidermal growth factor receptor expression for first-line chemotherapy
plus cetuximab in patients with head and neck and colorectal cancer: analysis of
data from the EXTREME and CRYSTAL studies. Eur J Cancer 49: 1161–
1168.
33. Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, et al. (2011) Evaluation of
EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab
in combination with chemotherapy in the first-line treatment of recurrent and/
or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Ann Oncol 22: 1078–1087.
Circulating Tumor Cells in Metastatic Head and Neck Carcinoma
PLOS ONE | www.plosone.org 9 August 2014 | Volume 9 | Issue 8 | e103918
